ABSTRACT
1
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by inflammation, vasculopathy, and fibrosis of the skin and internal organs. 2 SSc may cause damage in multiple organ systems, including the gastrointestinal tract, respiratory, and cardiovascular systems. RA and SSc are two different forms of inflammatory diseases associated with significant morbidity and increased mortality and both diseases are more common in females. [3] [4] [5] Fatigue is a common and disabling symptom in autoimmune rheumatic disorders including RA and SSc; however, assessment of fatigue is often overlooked. 6, 7 The pathophysiology of fatigue in RA and SSc is not well understood, but is thought to be multifactorial (including increased pain, poor physical function, sleep quality, and psychosocial factors). [8] [9] [10] [11] [12] Although fatigue is not a mandatory manifestation for the diagnosis of RA or SSc, persistent fatigue is an important clinical problem which may interfere with loss of functioning and health related quality of life (HRQoL) and contributes to the increased disease burden. [13] [14] [15] Several studies compared these two diseases in terms of clinical, laboratory and imaging aspects; however, level of fatigue which was assessed by single-item and multidimensional scales have not been evaluated comparatively. Therefore, in this study, we aimed to compare the levels of fatigue in RA and SSc and to assess the potential influence of fatigue on clinical variables. 16, 17 Patients with a prior diagnosis of psychiatric disorders or fibromyalgia or taking medications for these disorders, or who had uncontrolled diabetes or neurological disorders were excluded. All patients were biologic naive. Patients were examined and evaluated for disease specific and generic outcome measures including disease activity parameters, physical functions, psychological status, and HRQoL measures. Six-minute walking distance was noted in meters.
PATIENTS AND METHODS
Visual Analog Scale of pain (VAS-pain, 0-10 scale) within the last week was noted. Level of fatigue was assessed by Fatigue Severity Scale (FSS) and Multidimensional Assessment of Fatigue (MAF) scale, Short-Form 36 (SF-36)-vitality and VAS of fatigue (0-10 numeric scale). These were interviewed by the same experienced physician who was blind to clinical data.
The FSS and MAF are self-administered questionnaires to measure self-reported fatigue. FSS questionnaire contains nine statements that attempt to detect severity of fatigue and its effects on motivation, exercise, physical functioning, carrying out duties, interfering with work, family, or social life. This scale is a seven-point Likert scale: 1 (strongly disagree) and 7 (strongly agree). The scoring is performed by calculating the average of responses ranging from 1 to 9. Higher scores indicate more severe fatigue. 18 The questionnaire takes nearly two-three minutes to complete. Validity and reliability of Turkish version of FSS to assess fatigue have been shown in patients with fibromyalgia and multiple sclerosis. 19, 20 The MAF questionnaire is used to measure four dimensions of fatigue in the past week; severity, distress, timing, and degree of interference with activities of daily living (household chores, cooking, bathing, dressing, working, socializing, sexual activity, leisure and recreational activities, shopping, walking, and other exercising 21 The Turkish version of MAF is valid and reliable to detect the severity of 23 The study protocol was approved by the Erciyes University Faculty of Medicine Ethics Committee. A written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki.
Statistical analysis
All analyses were performed on a personal computer using IBM SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Normality of distributions was assessed by KolmogorovSmirnov test. Parameters and demographic variables in patients with RA and SSc were compared using t-test or chi-square test. Relationship between parameters was analyzed by Spearman or Pearson correlation tests. A p value of <0.05 was considered statistically significant.
RESULTS
Patients had similar age and sex, symptom duration, educational and smoking status, as well as functioning (Health Assessment Questionnaire) and health related quality of life (SF-36) ( Table 1) . Comorbid diseases (including controlled diabetes, hypertension, atherosclerotic heart disease, thyroid diseases alone or in combination) were present in 60.8% of patients with RA and 58.0% of patients Levels of fatigue which were assessed by VAS, SF-36-vitality, FSS, and MAF were quite similar between patients with RA and SSc ( Table 2) . Levels of fatigue, measured by different scales, were significantly correlated with physical functions and HRQoL measures and psychometric variables in both groups; however, the correlation coefficients were relatively higher in patients with RA (Table 3) .
DISCUSSION
In our study, we compared the level of fatigue in RA and SSc and assessed its potential influence on clinical variables. We showed that the level of fatigue was quite similar between patients with RA and SSc and significantly correlated with physical functions and HRQoL.
Fatigue is a major problem in patients with RA and SSc, and has a negative impact on HRQoL. 13, 15 Although fatigue is a common and disturbing symptom in patients with RA and SSc, assessment of fatigue is often ignored by physicians. 6, 7 Various questionnaires including single-item, multi-item, and multidimensional questionnaires were used to evaluate fatigue in patients with RA and SSc. Up to date, no consensus was reached on which questionnaire has to be used in RA or SSc to assess fatigue. Although Wolfe suggested that single-item VAS was similar or better than longer questionnaires in RA, 24 the common practice is in favor of using specific, multi-item and multidimensional scales of fatigue. 25, 26 In our study, the level of fatigue was assessed by using Turkish versions of MAF, FSS, SF-36-vitality subscore, and VAS of fatigue. To our knowledge, this is the first report comparing these two diseases in terms of fatigue by using various assessment tools.
The mechanism that leads to fatigue in RA and SSc is multifactorial. Pharmacological and non-pharmacological treatments were associated with decreased fatigue levels. [27] [28] [29] Small number of studies reported the effect of biologic therapies on fatigue levels in patients with RA. In a recent meta-analysis, Chauffier et al. 30 reported the effect of biologic agents on fatigue in RA; however, underscored that this effect was rather minor. Additionally, Pollard et al. 28 showed reduced fatigue levels with disease modifying antirheumatic drug treatment.
Furthermore, Mancuso et al. 31 suggested that fatigue severity (FSS scores) was associated with increased disability, anxiety and depression symptom, less social support and more social stress in patients with RA. Another study revealed that fatigue was strongly associated with functional disability, increased pain and depression symptoms, poor sleep, and lower hematocrit levels. 8 In patients with RA, increased pain, depression symptoms, female sex, longer symptom duration, 9 and sleep disturbances were shown as the significant predictors of increased fatigue. 11, 21 Nicassio et al. 32 showed that higher levels of disease activity, mood disturbance, and poor sleep quality had direct effect on fatigue, and also discussed the indirect cause and effect relationships of these factors on fatigue.
In SSc, cutaneous and internal organ involvements are the primary targets of treatment and unfortunately fatigue is generally an overlooked feature to assess or manage by clinicians. A few studies revealed the association of fatigue with decreased physical functions, sleep quality, increased pain, and depression symptoms in patients with SSc. 12, 33 Canadian Scleroderma Research Group reported that higher fatigue was significantly associated with the number of medical comorbidities, breathing problems, gastrointestinal symptoms, and current smoking. 34 Thombs et al. 7 showed that fatigue level in patients with SSc was higher than general population and cancer patients in remission; however, similar to patients under active treatment for cancer and patients with other rheumatic diseases.
Our study had some limitations. First, the number of patients was relatively small. We excluded patients with a history of or under treatment with biologics for the fact that these agents had major impact on fatigue levels. Secondly, we could only assess patients in a cross-sectional design. More robust results on fatigue and its correlation with clinical findings may be warranted in a longitudinal design. Although our study populations were matched for sex, number of male patients was relatively small which prohibited assessing sex specific differences on fatigue in separate sex groups.
In conclusion, patients with RA and SSc should be carefully evaluated for fatigue by using valid scales and the impact of fatigue on clinical measures should not be overlooked. Longitudinal follow-up of patients with different treatments may enhance our understanding for the possible cause and effect relationship of fatigue with other clinical manifestations.
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